Physician profile
John A Debello
NPI 1568402576
$4,320.27
in general payments reported to CMS, 2019-2025
23 companies · $939 in 2025
The $939 reported for 2025 was more than what 79% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $263 · 2021: $224 · 2022: $295 · 2023: $132 · 2024: $2,106 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923 · Travel and Lodging: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,923.19 |
| Travel and Lodging | $1,253.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,640.71 | 2024 | |
| Horizon Therapeutics Plc | $492.12 | 2020-2023 | Rayos, Krystexxa |
| Paratek Pharmaceuticals, INC. | $437.52 | 2022-2025 | Nuzyra |
| Arthrex, INC. | $288.20 | 2025 | |
| Gotham Surgical Solutions & Devices, INC. | $286.29 | 2025 | |
| Merck Sharp & Dohme LLC | $232.96 | 2019 | |
| Treace Medical Concepts, INC. | $219.03 | 2024-2025 | |
| Averitas Pharma INC. | $174.03 | 2024-2025 | Qutenza |
| Smith+Nephew, INC. | $149.09 | 2019-2020 | |
| Advanced Oxygen Therapy INC. | $65.91 | 2019-2022 | |
| Abbott Laboratories | $59.69 | 2022 | |
| Integra Lifesciences Corporation | $55.65 | 2019-2020 | |
| Organogenesis INC. | $36.00 | 2021-2022 | |
| Orthofix Medical, INC. | $30.56 | 2019-2021 | |
| Sandoz INC. | $19.94 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $19.26 | 2023 | Seglentis |
| Convatec INC. | $19.03 | 2021 | |
| Kerecis Limited | $17.36 | 2021 | |
| Novum Pharma, LLC | $16.52 | 2019 | |
| Nevro Corp. | $16.25 | 2023 | Senza |
| Dynasplint Systems INC. | $15.05 | 2023 | Dynasplint |
| Dermavant Sciences, INC. | $14.77 | 2024 | Vtama |
| Nabriva Therapeutics, Plc | $14.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Debello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.